Real estate & infrastructure
BBHVanEckINDEX
VanEck Biotech ETF
$249.80+0.97% vs prior close
17725052-WK
Price through Oct 27, 2026 · Flows through Oct 26, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 27, 2026. Holdings snapshot retrieved Oct 27, 2026.
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
BBH price
Source: Market tape, daily closes; price return, distributions not reinvested
Table
| Date | BBH close |
|---|---|
| Jul 27, 2026 | $204.07 |
| Jul 28, 2026 | $210.10 |
| Jul 29, 2026 | $208.64 |
| Jul 30, 2026 | $208.01 |
| Jul 31, 2026 | $205.55 |
| Aug 3, 2026 | $204.28 |
| Aug 4, 2026 | $208.03 |
| Aug 5, 2026 | $210.49 |
| Aug 6, 2026 | $210.67 |
| Aug 7, 2026 | $216.58 |
| Aug 10, 2026 | $219.79 |
| Aug 11, 2026 | $219.72 |
| Aug 12, 2026 | $220.27 |
| Aug 13, 2026 | $219.64 |
| Aug 14, 2026 | $218.04 |
| Aug 17, 2026 | $222.29 |
| Aug 18, 2026 | $224.48 |
| Aug 19, 2026 | $244.02 |
| Aug 20, 2026 | $237.11 |
| Aug 21, 2026 | $241.23 |
| Aug 24, 2026 | $240.41 |
| Aug 25, 2026 | $243.73 |
| Aug 26, 2026 | $242.67 |
| Aug 27, 2026 | $241.99 |
| Aug 28, 2026 | $236.48 |
| Aug 31, 2026 | $236.40 |
| Sep 1, 2026 | $239.49 |
| Sep 2, 2026 | $242.79 |
| Sep 3, 2026 | $243.73 |
| Sep 4, 2026 | $241.12 |
| Sep 8, 2026 | $232.34 |
| Sep 9, 2026 | $231.22 |
| Sep 10, 2026 | $228.64 |
| Sep 11, 2026 | $229.39 |
| Sep 14, 2026 | $232.02 |
| Sep 15, 2026 | $230.70 |
| Sep 16, 2026 | $231.17 |
| Sep 17, 2026 | $236.72 |
| Sep 18, 2026 | $234.14 |
| Sep 21, 2026 | $237.72 |
| Sep 22, 2026 | $242.03 |
| Sep 23, 2026 | $240.21 |
| Sep 24, 2026 | $243.78 |
| Sep 25, 2026 | $245.36 |
| Sep 28, 2026 | $245.34 |
| Sep 29, 2026 | $245.64 |
| Sep 30, 2026 | $244.57 |
| Oct 1, 2026 | $238.74 |
| Oct 2, 2026 | $237.45 |
| Oct 5, 2026 | $240.53 |
| Oct 6, 2026 | $236.30 |
| Oct 7, 2026 | $237.87 |
| Oct 8, 2026 | $234.03 |
| Oct 9, 2026 | $240.47 |
| Oct 12, 2026 | $239.22 |
| Oct 13, 2026 | $235.92 |
| Oct 14, 2026 | $241.07 |
| Oct 15, 2026 | $246.49 |
| Oct 16, 2026 | $241.36 |
| Oct 19, 2026 | $241.14 |
| Oct 20, 2026 | $248.78 |
| Oct 21, 2026 | $250.46 |
| Oct 22, 2026 | $248.41 |
| Oct 23, 2026 | $246.57 |
| Oct 26, 2026 | $247.39 |
| Oct 27, 2026 | $249.80 |
Weekly net flows, 3M
Net inflow over the range: +$22M
- Inflow / above zero
- Outflow / below zero
Source: Daily creation and redemption records
Show as table
| Label | Value ($) |
|---|---|
| Jul 27 | $0 |
| Aug 3 | $0 |
| Aug 10 | $0 |
| Aug 17 | $7.2M |
| Aug 24 | $2.4M |
| Aug 31 | $9.7M |
| Sep 7 | −$4.6M |
| Sep 14 | $23.6M |
| Sep 21 | −$26.1M |
| Sep 28 | $2.4M |
| Oct 5 | $2.3M |
| Oct 12 | $0 |
| Oct 19 | $4.9M |
| Oct 26 | $0 |
The desk’s read
Money keeps arriving — +$10M of net inflows over the past month, about 1.9% of the fund's asset base, while the price has returned +32.0% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
$504Massets under management
0.35%expense ratio · $35 per $10,000 a year
+$10Mnet flow, trailing month
12Kavg daily volume, 30 days
26holdings · US-domiciled
1999listed November 23, 1999 · beta 0.65
The book at a glance
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
Holdings
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMGNAMGEN | 16.31% | $447.95 | +0.7% | ||
| 2 | GILDGILEAD SCIENCES | 13.68% | $159.08 | +0.2% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 8.17% | $521.03 | +0.7% | ||
| 4 | REGNREGENERON PHARMACEUTICALS | 6.84% | $816.10 | +1.0% | ||
| 5 | MRNAMODERNA | 6.25% | $207.97 | +4.6% | ||
| 6 | NTRANATERA | 4.77% | $410.82 | +1.5% | ||
| 7 | IQVIQVIA HOLDINGS | 4.60% | $271.55 | -0.7% | ||
| 8 | ARGXARGENX SE | 4.15% | $882.48 | +1.5% | ||
| 9 | ILMNILLUMINA | 3.95% | $279.47 | +3.1% | ||
| 10 | RVMDREVOLUTION MEDICINES | 3.81% | $186.22 | +1.3% | ||
| 11 | BIIBBIOGEN | 3.01% | $252.73 | +0.2% | ||
| 12 | GHGUARDANT HEALTH | 2.83% | $178.06 | +2.8% | ||
| 13 | ONCBeiGene | 2.82% | $366.06 | -1.3% | ||
| 14 | ALNYALNYLAM PHARMACEUTICALS | 2.43% | $226.79 | -0.4% | ||
| 15 | UTHRUNITED THERAPEUTICS | 2.41% | $591.20 | -0.3% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 26Sector weights
- Healthcare100%
- Health Technology86.57%
- Commercial Services7.67%
- Health Services5.76%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 86.57% |
| Commercial Services | 7.67% |
| Health Services | 5.76% |
Country weights
- United States93.37%
- Ireland4.43%
- China3.87%
- Netherlands2.82%
- Germany1.95%
- Spain1.67%
- Hong Kong1.62%
- Switzerland0.81%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| United States | 93.37% |
| Ireland | 4.43% |
| China | 3.87% |
| Netherlands | 2.82% |
| Germany | 1.95% |
| Spain | 1.67% |
| Hong Kong | 1.62% |
| Switzerland | 0.81% |
Performance
| 1 week | -0.3% |
| 1 month | +1.8% |
| 3 months | +22.4% |
| 6 months | +34.5% |
| YTD | +32.0% |
| 1 year | +40.3% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
Net flows
| 1 week | +$2M |
| 1 month | +$10M |
| 3 months | +$22M |
| YTD | +$15M |
| 1 year | +$16M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Source: Daily creation/redemption records, trailing twelve months
Show as table
| Label | Value ($) |
|---|---|
| Nov | $2M |
| Dec | −$360K |
| Jan | $100K |
| Feb | −$2M |
| Mar | $140K |
| Apr | −$1.9M |
| May | −$3.7M |
| Jun | $0 |
| Jul | $0 |
| Aug | $9.6M |
| Sep | $2.6M |
| Oct | $9.6M |
The risk read
25%realized volatility, 30 days (annualized)
22%realized volatility, 1 year
-10.5%deepest fall from a peak, 1 year
-0.3%latest close versus that peak
The top holding is 16.3% of the book; the top ten carry 73%. Spread across 25+ names, it behaves like roughly 13 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Options tape
65calls · latest snapshot
7puts · latest snapshot
0.11put/call ratio
6Kshares traded
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $53M |
| AMGN AMGEN | $64M | $2M |
| INSM INSMED | $8M | $5M |
| TEM TEMPUS AI INC | $4M | $3M |
| NTRA NATERA | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
The case against BBH
Due diligence cuts both ways. These funds sit on the same shelf and beat BBH on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $40.7B | +$609M | -32bp on fee · 81× the assets · +$609M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -32bp on fee · 36× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -31bp on fee · 64× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$47M | -31bp on fee · 47× the assets · +$47M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 37× the assets · +$412M in over the month | Head-to-head |
